Retatrutide for coronary artery disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 25 Apr 2024: Trial registered, NCT06383390
  2. 30 Apr 2024: Trial started, NCT06383390

The trials

NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

State
Under way
Phase
Phase 3
People
10,000 planned
Started
30 Apr 2024
Primary completion
Feb 2029
Arms
Retatrutide
Results
None posted
  1. 25 Apr 2024: Trial registered
  2. 30 Apr 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Retatrutide (LY3437943).

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.